Nanomerics

Executive Summary

Nanomerics is a clinical-stage biopharmaceutical company leveraging its proprietary Molecular Envelope Technology (MET) to develop targeted nanomedicines for ophthalmology and central nervous system (CNS) disorders. The MET platform enhances drug delivery to the site of action, improving efficacy and reducing side effects. The company’s lead candidate, targeting a chronic ophthalmic condition, is currently in Phase 3 trials, with multiple preclinical and clinical programs addressing high unmet needs in CNS diseases such as Parkinson’s and Alzheimer’s. Nanomerics’ approach aims to enable safer and more effective therapies by overcoming biological barriers, including the blood-brain barrier. The company is headquartered in London, UK, and benefits from a strong intellectual property portfolio covering its MET-based formulations. Nanomerics has advanced its lead ophthalmology program to Phase 3, supported by favorable Phase 2 data demonstrating superior bioavailability and tolerability compared to standard of care. The company is actively seeking strategic partnerships to expand the MET platform into additional therapeutic areas, including gene therapy and oncology. With a focus on precision medicine, Nanomerics is positioned to address significant market opportunities in ophthalmology and neurology. Upcoming milestones include the readout of Phase 3 data, which could validate the MET platform and unlock further collaboration interest. The company’s private status limits visibility, but its progress in late-stage trials suggests a pivotal period ahead.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 Topline Data for Lead Ophthalmology Candidate50% success
• Q2 2027Regulatory Filing for CNS Candidate30% success
• Q4 2026Strategic Partnership for MET Platform40% success